Dual Benefits and Risks: Tirzepatide's Impact on Pancreatic Function

Abstract Tirzepatide is a new GLP-1 and GIP receptor agonist. We have seen good results in managing type 2 diabetes and obesity using Tirzepatide by improving glycemic control and promoting significant weight loss. The effects on the pancreas include enhanced glucose-dependent insulin secretion, reduced glucagon production, and potential protective actions on beta-cell function and survival among other. Rare cases of acute pancreatitis, such as severe necrotizing pancreatitis, have been reported however. Thus, we need close monitoring of patients for abdominal pain, nausea, or vomiting. While tirzepatide has benefits for metabolic health, its use requires careful supervision to lower the potential pancreatic risks. This highlights the importance of balancing its therapeutic advantages with vigilant monitoring for adverse effects.